KR20200085837A - 유전적 간질 질환 치료에 사용하기 위한 가낙솔론의 용도 - Google Patents
유전적 간질 질환 치료에 사용하기 위한 가낙솔론의 용도 Download PDFInfo
- Publication number
- KR20200085837A KR20200085837A KR1020207016409A KR20207016409A KR20200085837A KR 20200085837 A KR20200085837 A KR 20200085837A KR 1020207016409 A KR1020207016409 A KR 1020207016409A KR 20207016409 A KR20207016409 A KR 20207016409A KR 20200085837 A KR20200085837 A KR 20200085837A
- Authority
- KR
- South Korea
- Prior art keywords
- day
- epilepsy
- optionally substituted
- less
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010015037 epilepsy Diseases 0.000 title claims abstract description 253
- 230000002068 genetic effect Effects 0.000 title abstract description 39
- 238000011282 treatment Methods 0.000 title description 96
- 206010010904 Convulsion Diseases 0.000 claims abstract description 360
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 claims abstract description 121
- 229960000249 pregnenolone Drugs 0.000 claims abstract description 121
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 104
- 238000000034 method Methods 0.000 claims abstract description 98
- 241000124008 Mammalia Species 0.000 claims abstract description 57
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 claims abstract 12
- PGTVWKLGGCQMBR-FLBATMFCSA-N Ganaxolone Chemical compound C([C@@H]1CC2)[C@](C)(O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 PGTVWKLGGCQMBR-FLBATMFCSA-N 0.000 claims description 210
- 229950006567 ganaxolone Drugs 0.000 claims description 209
- 102100036389 Protocadherin-19 Human genes 0.000 claims description 140
- 239000002858 neurotransmitter agent Substances 0.000 claims description 104
- 208000027412 CDKL5-deficiency disease Diseases 0.000 claims description 74
- AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 claims description 66
- 230000007958 sleep Effects 0.000 claims description 66
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims description 54
- 201000007547 Dravet syndrome Diseases 0.000 claims description 53
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 claims description 53
- 208000014644 Brain disease Diseases 0.000 claims description 50
- 208000011580 syndromic disease Diseases 0.000 claims description 49
- 208000035475 disorder Diseases 0.000 claims description 45
- MENQCIVHHONJLU-FZCSVUEKSA-N [(3s,5s,8r,9s,10s,13s,14s,17s)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound C([C@@H]1CC2)[C@@H](OS(O)(=O)=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 MENQCIVHHONJLU-FZCSVUEKSA-N 0.000 claims description 44
- 239000001257 hydrogen Substances 0.000 claims description 41
- 229910052739 hydrogen Inorganic materials 0.000 claims description 41
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 208000032274 Encephalopathy Diseases 0.000 claims description 39
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 35
- 150000002431 hydrogen Chemical class 0.000 claims description 33
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 31
- 230000001965 increasing effect Effects 0.000 claims description 27
- 230000001037 epileptic effect Effects 0.000 claims description 21
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 20
- 208000006289 Rett Syndrome Diseases 0.000 claims description 19
- 125000003107 substituted aryl group Chemical group 0.000 claims description 19
- 206010021750 Infantile Spasms Diseases 0.000 claims description 18
- 125000004043 oxo group Chemical group O=* 0.000 claims description 18
- 208000005809 status epilepticus Diseases 0.000 claims description 18
- 201000006791 West syndrome Diseases 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- AURFZBICLPNKBZ-YZRLXODZSA-N 3alpha-hydroxy-5beta-pregnan-20-one Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-YZRLXODZSA-N 0.000 claims description 15
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 15
- 208000035899 Infantile spasms syndrome Diseases 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 13
- 210000004556 brain Anatomy 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 229950007402 eltanolone Drugs 0.000 claims description 11
- 208000036626 Mental retardation Diseases 0.000 claims description 10
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 claims description 10
- 238000004458 analytical method Methods 0.000 claims description 9
- 230000002920 convulsive effect Effects 0.000 claims description 9
- 230000002151 myoclonic effect Effects 0.000 claims description 9
- 201000008009 Early infantile epileptic encephalopathy Diseases 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 208000009575 Angelman syndrome Diseases 0.000 claims description 7
- 206010071545 Early infantile epileptic encephalopathy with burst-suppression Diseases 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 7
- 230000006735 deficit Effects 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 5
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 5
- 208000008310 infantile epileptic-dyskinetic encephalopathy Diseases 0.000 claims description 5
- XMRPGKVKISIQBV-UHFFFAOYSA-N (+-)-5- Pregnane-3,20-dione Natural products C1CC2CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 XMRPGKVKISIQBV-UHFFFAOYSA-N 0.000 claims description 4
- XMRPGKVKISIQBV-BJMCWZGWSA-N 5alpha-pregnane-3,20-dione Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 XMRPGKVKISIQBV-BJMCWZGWSA-N 0.000 claims description 4
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 101001072243 Homo sapiens Protocadherin-19 Proteins 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 1
- 206010064571 Gene mutation Diseases 0.000 abstract description 18
- 101150032457 CDKL5 gene Proteins 0.000 abstract description 15
- 101100439048 Homo sapiens CDKL5 gene Proteins 0.000 abstract description 15
- 101710157832 Protocadherin-19 Proteins 0.000 description 138
- 239000002245 particle Substances 0.000 description 113
- 239000000203 mixture Substances 0.000 description 109
- OZZAYJQNMKMUSD-DMISRAGPSA-N pregnenolone succinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 OZZAYJQNMKMUSD-DMISRAGPSA-N 0.000 description 109
- 238000009472 formulation Methods 0.000 description 79
- 239000002775 capsule Substances 0.000 description 70
- 239000001961 anticonvulsive agent Substances 0.000 description 59
- AURFZBICLPNKBZ-SYBPFIFISA-N brexanolone Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-SYBPFIFISA-N 0.000 description 57
- 239000000725 suspension Substances 0.000 description 56
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 54
- 239000006185 dispersion Substances 0.000 description 53
- 102100034746 Cyclin-dependent kinase-like 5 Human genes 0.000 description 51
- 101710178912 Cyclin-dependent kinase-like 5 Proteins 0.000 description 50
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 50
- 230000035772 mutation Effects 0.000 description 48
- 230000000694 effects Effects 0.000 description 47
- 230000036470 plasma concentration Effects 0.000 description 44
- 230000008859 change Effects 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 42
- 108010005551 GABA Receptors Proteins 0.000 description 32
- 102000005915 GABA Receptors Human genes 0.000 description 32
- 239000003814 drug Substances 0.000 description 32
- 201000010099 disease Diseases 0.000 description 29
- 229940079593 drug Drugs 0.000 description 28
- -1 minodilone Chemical compound 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 27
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 26
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 26
- 125000004432 carbon atom Chemical group C* 0.000 description 25
- 229940100692 oral suspension Drugs 0.000 description 25
- 230000009467 reduction Effects 0.000 description 23
- 208000034332 Body integrity dysphoria Diseases 0.000 description 22
- 241000282412 Homo Species 0.000 description 21
- 229960003965 antiepileptics Drugs 0.000 description 21
- 101100028812 Homo sapiens PCDH19 gene Proteins 0.000 description 20
- 101150105943 PCDH19 gene Proteins 0.000 description 20
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 20
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 20
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 20
- 230000002496 gastric effect Effects 0.000 description 19
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 19
- 230000003542 behavioural effect Effects 0.000 description 18
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 18
- 150000003431 steroids Chemical class 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 230000006872 improvement Effects 0.000 description 17
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 17
- 229940049706 benzodiazepine Drugs 0.000 description 16
- 239000012530 fluid Substances 0.000 description 16
- 230000001976 improved effect Effects 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 201000006347 Intellectual Disability Diseases 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 230000004044 response Effects 0.000 description 15
- 239000013543 active substance Substances 0.000 description 14
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 14
- 208000019116 sleep disease Diseases 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000007900 aqueous suspension Substances 0.000 description 13
- 150000001557 benzodiazepines Chemical class 0.000 description 13
- 230000002354 daily effect Effects 0.000 description 13
- 230000012010 growth Effects 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 229940125681 anticonvulsant agent Drugs 0.000 description 12
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical group OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 229940100691 oral capsule Drugs 0.000 description 12
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
- 230000000946 synaptic effect Effects 0.000 description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000000537 electroencephalography Methods 0.000 description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 11
- 239000002105 nanoparticle Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 229920000858 Cyclodextrin Polymers 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- XRYVAQQLDYTHCL-UHFFFAOYSA-N Marini Chemical compound O1C=2C(CC(CC=C(C)C)C(C)=C)=C(O)C=C(O)C=2C(=O)CC1C1=CC=C(O)C=C1O XRYVAQQLDYTHCL-UHFFFAOYSA-N 0.000 description 10
- 230000001773 anti-convulsant effect Effects 0.000 description 10
- 210000003169 central nervous system Anatomy 0.000 description 10
- 230000001149 cognitive effect Effects 0.000 description 10
- 239000008139 complexing agent Substances 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 10
- 210000002569 neuron Anatomy 0.000 description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 10
- 239000000186 progesterone Substances 0.000 description 10
- 229960003387 progesterone Drugs 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 description 9
- 206010012559 Developmental delay Diseases 0.000 description 9
- 239000004372 Polyvinyl alcohol Substances 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000027455 binding Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 125000000524 functional group Chemical group 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 235000012054 meals Nutrition 0.000 description 9
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 9
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 9
- 229960002216 methylparaben Drugs 0.000 description 9
- 229920002451 polyvinyl alcohol Polymers 0.000 description 9
- 229940068984 polyvinyl alcohol Drugs 0.000 description 9
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 9
- 230000009885 systemic effect Effects 0.000 description 9
- 238000004448 titration Methods 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- 206010001497 Agitation Diseases 0.000 description 8
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 210000001766 X chromosome Anatomy 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 235000010980 cellulose Nutrition 0.000 description 8
- 229920002678 cellulose Polymers 0.000 description 8
- 239000001913 cellulose Substances 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 239000003193 general anesthetic agent Substances 0.000 description 8
- 229920001477 hydrophilic polymer Polymers 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 230000001537 neural effect Effects 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 8
- 239000000932 sedative agent Substances 0.000 description 8
- 235000011888 snacks Nutrition 0.000 description 8
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 8
- 235000010234 sodium benzoate Nutrition 0.000 description 8
- 239000004299 sodium benzoate Substances 0.000 description 8
- 239000000080 wetting agent Substances 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 7
- 208000005392 Spasm Diseases 0.000 description 7
- 208000023944 Sudden Unexpected Death in Epilepsy Diseases 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 229960003305 alfaxalone Drugs 0.000 description 7
- 229940035674 anesthetics Drugs 0.000 description 7
- 230000003556 anti-epileptic effect Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 208000010877 cognitive disease Diseases 0.000 description 7
- 239000006071 cream Substances 0.000 description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 230000002045 lasting effect Effects 0.000 description 7
- 230000033001 locomotion Effects 0.000 description 7
- JWMFYGXQPXQEEM-WZBAXQLOSA-N pregnane Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](CC)[C@@]1(C)CC2 JWMFYGXQPXQEEM-WZBAXQLOSA-N 0.000 description 7
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 7
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 7
- 229960003415 propylparaben Drugs 0.000 description 7
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 6
- 206010003805 Autism Diseases 0.000 description 6
- 208000020706 Autistic disease Diseases 0.000 description 6
- 208000028698 Cognitive impairment Diseases 0.000 description 6
- 102400000739 Corticotropin Human genes 0.000 description 6
- 101800000414 Corticotropin Proteins 0.000 description 6
- 208000024658 Epilepsy syndrome Diseases 0.000 description 6
- 208000002877 Epileptic Syndromes Diseases 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 206010071350 Seizure cluster Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 6
- 239000007963 capsule composition Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 6
- 229960000258 corticotropin Drugs 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 235000003599 food sweetener Nutrition 0.000 description 6
- 239000007903 gelatin capsule Substances 0.000 description 6
- 230000001771 impaired effect Effects 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 231100000682 maximum tolerated dose Toxicity 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 229940083037 simethicone Drugs 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 5
- USPYDUPOCUYHQL-VEVMSBRDSA-N 5beta-dihydrodeoxycorticosterone Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 USPYDUPOCUYHQL-VEVMSBRDSA-N 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 239000005711 Benzoic acid Substances 0.000 description 5
- 102100028737 CAP-Gly domain-containing linker protein 1 Human genes 0.000 description 5
- 241000207199 Citrus Species 0.000 description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 description 5
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 5
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 5
- 108700024394 Exon Proteins 0.000 description 5
- 101000767052 Homo sapiens CAP-Gly domain-containing linker protein 1 Proteins 0.000 description 5
- 102000029749 Microtubule Human genes 0.000 description 5
- 108091022875 Microtubule Proteins 0.000 description 5
- 239000004376 Sucralose Substances 0.000 description 5
- RHQQHZQUAMFINJ-DTDWNVJFSA-N Tetrahydrocorticosterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 RHQQHZQUAMFINJ-DTDWNVJFSA-N 0.000 description 5
- 102000003734 Voltage-Gated Potassium Channels Human genes 0.000 description 5
- 108090000013 Voltage-Gated Potassium Channels Proteins 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000003444 anaesthetic effect Effects 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 229940125717 barbiturate Drugs 0.000 description 5
- 235000010233 benzoic acid Nutrition 0.000 description 5
- 229960000623 carbamazepine Drugs 0.000 description 5
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000020971 citrus fruits Nutrition 0.000 description 5
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 229940126534 drug product Drugs 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229960001848 lamotrigine Drugs 0.000 description 5
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 5
- 210000004688 microtubule Anatomy 0.000 description 5
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 5
- 229960003793 midazolam Drugs 0.000 description 5
- 239000006186 oral dosage form Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000003997 social interaction Effects 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 235000019408 sucralose Nutrition 0.000 description 5
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 230000001256 tonic effect Effects 0.000 description 5
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 5
- RHQQHZQUAMFINJ-UHFFFAOYSA-N (3alpha,5alpha,11beta)-3,11,21-Trihydroxypregnan-20-one Natural products C1C(O)CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC21 RHQQHZQUAMFINJ-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- WQNHWIYLCRZRLR-UHFFFAOYSA-N 2-(3-hydroxy-2,5-dioxooxolan-3-yl)acetic acid Chemical compound OC(=O)CC1(O)CC(=O)OC1=O WQNHWIYLCRZRLR-UHFFFAOYSA-N 0.000 description 4
- MENQCIVHHONJLU-YZRLXODZSA-N 3alpha-Hydroxy-5beta-pregnane-20-one sulfate Chemical compound C([C@H]1CC2)[C@H](OS(O)(=O)=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 MENQCIVHHONJLU-YZRLXODZSA-N 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 206010003628 Atonic seizures Diseases 0.000 description 4
- 102100029962 CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase Human genes 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010051290 Central nervous system lesion Diseases 0.000 description 4
- 102100031265 Chromodomain-helicase-DNA-binding protein 2 Human genes 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 102000027484 GABAA receptors Human genes 0.000 description 4
- 108091008681 GABAA receptors Proteins 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- 102100024013 Golgi SNAP receptor complex member 2 Human genes 0.000 description 4
- 101000863898 Homo sapiens CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase Proteins 0.000 description 4
- 101001009074 Homo sapiens Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Proteins 0.000 description 4
- 101000684826 Homo sapiens Sodium channel protein type 2 subunit alpha Proteins 0.000 description 4
- 206010021118 Hypotonia Diseases 0.000 description 4
- 102000004310 Ion Channels Human genes 0.000 description 4
- 108090000862 Ion Channels Proteins 0.000 description 4
- 102100026519 Lamin-B2 Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000007379 Muscle Hypotonia Diseases 0.000 description 4
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 206010062519 Poor quality sleep Diseases 0.000 description 4
- 102100027376 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 241001290151 Prunus avium subsp. avium Species 0.000 description 4
- 102100032771 Serine/threonine-protein kinase SIK1 Human genes 0.000 description 4
- 102100023150 Sodium channel protein type 2 subunit alpha Human genes 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 206010043994 Tonic convulsion Diseases 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000000949 anxiolytic effect Effects 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 229960004853 betadex Drugs 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000021152 breakfast Nutrition 0.000 description 4
- 235000019693 cherries Nutrition 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229960003529 diazepam Drugs 0.000 description 4
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
- 235000021158 dinner Nutrition 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 229960003472 felbamate Drugs 0.000 description 4
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 description 4
- 108010052219 lamin B2 Proteins 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 229960002900 methylcellulose Drugs 0.000 description 4
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229960001816 oxcarbazepine Drugs 0.000 description 4
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 229920001987 poloxamine Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 4
- 229940125723 sedative agent Drugs 0.000 description 4
- 230000001624 sedative effect Effects 0.000 description 4
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 210000000225 synapse Anatomy 0.000 description 4
- 229960000604 valproic acid Drugs 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100036799 Adhesion G-protein coupled receptor V1 Human genes 0.000 description 3
- 102100037399 Alanine-tRNA ligase, cytoplasmic Human genes 0.000 description 3
- 102100024085 Alpha-aminoadipic semialdehyde dehydrogenase Human genes 0.000 description 3
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 3
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 3
- 102100035430 Ceramide synthase 1 Human genes 0.000 description 3
- 108010062745 Chloride Channels Proteins 0.000 description 3
- 102000011045 Chloride Channels Human genes 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 235000005979 Citrus limon Nutrition 0.000 description 3
- 244000131522 Citrus pyriformis Species 0.000 description 3
- 240000000560 Citrus x paradisi Species 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 102100024342 Contactin-2 Human genes 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 102100027597 DOMON domain-containing protein FRRS1L Human genes 0.000 description 3
- 102100021236 Dynamin-1 Human genes 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102100035650 Extracellular calcium-sensing receptor Human genes 0.000 description 3
- 102100022688 GATOR complex protein DEPDC5 Human genes 0.000 description 3
- 101000690235 Homo sapiens Alpha-aminoadipic semialdehyde dehydrogenase Proteins 0.000 description 3
- 101000862412 Homo sapiens DOMON domain-containing protein FRRS1L Proteins 0.000 description 3
- 101000973111 Homo sapiens E3 ubiquitin-protein ligase NHLRC1 Proteins 0.000 description 3
- 101000904234 Homo sapiens Golgi SNAP receptor complex member 2 Proteins 0.000 description 3
- 101000581402 Homo sapiens Melanin-concentrating hormone receptor 1 Proteins 0.000 description 3
- 101000944018 Homo sapiens Potassium channel subfamily T member 1 Proteins 0.000 description 3
- 101000754240 Homo sapiens Protein ARV1 Proteins 0.000 description 3
- 101000654381 Homo sapiens Sodium channel protein type 8 subunit alpha Proteins 0.000 description 3
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 description 3
- 101000684813 Homo sapiens Sodium channel subunit beta-1 Proteins 0.000 description 3
- 101000788505 Homo sapiens TBC1 domain family member 24 Proteins 0.000 description 3
- 101000983947 Homo sapiens Voltage-dependent L-type calcium channel subunit beta-4 Proteins 0.000 description 3
- 101000935117 Homo sapiens Voltage-dependent P/Q-type calcium channel subunit alpha-1A Proteins 0.000 description 3
- 101000932804 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1H Proteins 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 3
- 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 235000006679 Mentha X verticillata Nutrition 0.000 description 3
- 235000002899 Mentha suaveolens Nutrition 0.000 description 3
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 208000002033 Myoclonus Diseases 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 102100029128 PR domain zinc finger protein 8 Human genes 0.000 description 3
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 229920003072 Plasdone™ povidone Polymers 0.000 description 3
- 102100033508 Potassium channel subfamily T member 1 Human genes 0.000 description 3
- 102100021622 Protein ARV1 Human genes 0.000 description 3
- 208000035977 Rare disease Diseases 0.000 description 3
- 208000036070 Rare genetic epilepsy Diseases 0.000 description 3
- 102100033221 Rho guanine nucleotide exchange factor 9 Human genes 0.000 description 3
- 102000037054 SLC-Transporter Human genes 0.000 description 3
- 108091006207 SLC-Transporter Proteins 0.000 description 3
- 102000037055 SLC1 Human genes 0.000 description 3
- 206010039897 Sedation Diseases 0.000 description 3
- 102100031371 Sodium channel protein type 8 subunit alpha Human genes 0.000 description 3
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 description 3
- 102100023732 Sodium channel subunit beta-1 Human genes 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 102100025233 TBC1 domain family member 24 Human genes 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 102100033095 Translation factor GUF1, mitochondrial Human genes 0.000 description 3
- 102100025836 Voltage-dependent L-type calcium channel subunit beta-4 Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000016571 aggressive behavior Effects 0.000 description 3
- XWYBFXIUISNTQG-VKMGZQQJSA-N alfadolone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CC[C@H]21 XWYBFXIUISNTQG-VKMGZQQJSA-N 0.000 description 3
- 230000003281 allosteric effect Effects 0.000 description 3
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000573 anti-seizure effect Effects 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 208000008784 apnea Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 208000029560 autism spectrum disease Diseases 0.000 description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000004641 brain development Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229960003120 clonazepam Drugs 0.000 description 3
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000012738 dissolution medium Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 208000016361 genetic disease Diseases 0.000 description 3
- 229920001903 high density polyethylene Polymers 0.000 description 3
- 239000004700 high-density polyethylene Substances 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000000147 hypnotic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 235000020887 ketogenic diet Nutrition 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 102000006240 membrane receptors Human genes 0.000 description 3
- 108020004084 membrane receptors Proteins 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- NCGLTZSBTFVVAW-KNXRZYMVSA-N minaxolone Chemical compound C1[C@@H](N(C)C)[C@@H]2[C@@]3(C)C[C@H](OCC)[C@@H](O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](C(C)=O)[C@]21C NCGLTZSBTFVVAW-KNXRZYMVSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 239000008184 oral solid dosage form Substances 0.000 description 3
- 229940096978 oral tablet Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229960002695 phenobarbital Drugs 0.000 description 3
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
- 229960002036 phenytoin Drugs 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229940126027 positive allosteric modulator Drugs 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 3
- 230000036280 sedation Effects 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 3
- 210000001186 vagus nerve Anatomy 0.000 description 3
- HARRKNSQXBRBGZ-GVKWWOCJSA-N zuranolone Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CC[C@@](C)(O)C[C@H]4CC3)CC[C@@]21C)CN1C=C(C#N)C=N1 HARRKNSQXBRBGZ-GVKWWOCJSA-N 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- CBMYJHIOYJEBSB-YSZCXEEOSA-N 5alpha-androstane-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 CBMYJHIOYJEBSB-YSZCXEEOSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 102000017905 ADRA2B Human genes 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 2
- 102100028215 BTB/POZ domain-containing protein KCTD7 Human genes 0.000 description 2
- 102000014817 CACNA1A Human genes 0.000 description 2
- 102000014835 CACNA1H Human genes 0.000 description 2
- 102100023073 Calcium-activated potassium channel subunit alpha-1 Human genes 0.000 description 2
- 102100026793 Carboxypeptidase A6 Human genes 0.000 description 2
- 101710146189 Ceramide synthase 1 Proteins 0.000 description 2
- 208000017033 Cerebral visual impairment Diseases 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 102100023509 Chloride channel protein 2 Human genes 0.000 description 2
- 101710170295 Chromodomain-helicase-DNA-binding protein 2 Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 102100026891 Cystatin-B Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- 102000003849 Cytochrome P450 Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 102100024351 Dedicator of cytokinesis protein 7 Human genes 0.000 description 2
- 208000027219 Deficiency disease Diseases 0.000 description 2
- 208000035976 Developmental Disabilities Diseases 0.000 description 2
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 102100022554 E3 ubiquitin-protein ligase NHLRC1 Human genes 0.000 description 2
- 102100029060 EF-hand domain-containing protein 1 Human genes 0.000 description 2
- 102100029108 Elongation factor 1-alpha 2 Human genes 0.000 description 2
- 206010015039 Epilepsy congenital Diseases 0.000 description 2
- 244000004281 Eucalyptus maculata Species 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- 102100028417 Fibroblast growth factor 12 Human genes 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108090000839 GABA-A Receptors Proteins 0.000 description 2
- 102000004300 GABA-A Receptors Human genes 0.000 description 2
- 102000017696 GABRA1 Human genes 0.000 description 2
- 102000017690 GABRB1 Human genes 0.000 description 2
- 102000017707 GABRB3 Human genes 0.000 description 2
- 102000017706 GABRD Human genes 0.000 description 2
- 102000017703 GABRG2 Human genes 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 2
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 2
- 102100022626 Glutamate receptor ionotropic, NMDA 2D Human genes 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 102100025296 Guanine nucleotide-binding protein G(o) subunit alpha Human genes 0.000 description 2
- 229920003114 HPC-L Polymers 0.000 description 2
- 229920003115 HPC-SL Polymers 0.000 description 2
- 101000928167 Homo sapiens Adhesion G-protein coupled receptor V1 Proteins 0.000 description 2
- 101000879354 Homo sapiens Alanine-tRNA ligase, cytoplasmic Proteins 0.000 description 2
- 101000929512 Homo sapiens Alpha-2B adrenergic receptor Proteins 0.000 description 2
- 101001007222 Homo sapiens BTB/POZ domain-containing protein KCTD7 Proteins 0.000 description 2
- 101001049859 Homo sapiens Calcium-activated potassium channel subunit alpha-1 Proteins 0.000 description 2
- 101000910782 Homo sapiens Carboxypeptidase A6 Proteins 0.000 description 2
- 101000906633 Homo sapiens Chloride channel protein 2 Proteins 0.000 description 2
- 101000777079 Homo sapiens Chromodomain-helicase-DNA-binding protein 2 Proteins 0.000 description 2
- 101000909516 Homo sapiens Contactin-2 Proteins 0.000 description 2
- 101000945692 Homo sapiens Cyclin-dependent kinase-like 5 Proteins 0.000 description 2
- 101000875170 Homo sapiens Cytochrome P450 2A6 Proteins 0.000 description 2
- 101001052952 Homo sapiens Dedicator of cytokinesis protein 7 Proteins 0.000 description 2
- 101000880945 Homo sapiens Down syndrome cell adhesion molecule Proteins 0.000 description 2
- 101000817604 Homo sapiens Dynamin-1 Proteins 0.000 description 2
- 101000840938 Homo sapiens EF-hand domain-containing protein 1 Proteins 0.000 description 2
- 101000841231 Homo sapiens Elongation factor 1-alpha 2 Proteins 0.000 description 2
- 101000866287 Homo sapiens Excitatory amino acid transporter 2 Proteins 0.000 description 2
- 101000917234 Homo sapiens Fibroblast growth factor 12 Proteins 0.000 description 2
- 101001044724 Homo sapiens GATOR complex protein DEPDC5 Proteins 0.000 description 2
- 101000893331 Homo sapiens Gamma-aminobutyric acid receptor subunit alpha-1 Proteins 0.000 description 2
- 101001001362 Homo sapiens Gamma-aminobutyric acid receptor subunit beta-1 Proteins 0.000 description 2
- 101001073597 Homo sapiens Gamma-aminobutyric acid receptor subunit beta-3 Proteins 0.000 description 2
- 101001073587 Homo sapiens Gamma-aminobutyric acid receptor subunit delta Proteins 0.000 description 2
- 101000926813 Homo sapiens Gamma-aminobutyric acid receptor subunit gamma-2 Proteins 0.000 description 2
- 101001125242 Homo sapiens Glutamate receptor ionotropic, NMDA 2A Proteins 0.000 description 2
- 101000972850 Homo sapiens Glutamate receptor ionotropic, NMDA 2B Proteins 0.000 description 2
- 101000972840 Homo sapiens Glutamate receptor ionotropic, NMDA 2D Proteins 0.000 description 2
- 101000857837 Homo sapiens Guanine nucleotide-binding protein G(o) subunit alpha Proteins 0.000 description 2
- 101000834851 Homo sapiens KICSTOR complex protein SZT2 Proteins 0.000 description 2
- 101000652814 Homo sapiens Lactosylceramide alpha-2,3-sialyltransferase Proteins 0.000 description 2
- 101000782865 Homo sapiens Neuronal acetylcholine receptor subunit alpha-2 Proteins 0.000 description 2
- 101000745167 Homo sapiens Neuronal acetylcholine receptor subunit alpha-4 Proteins 0.000 description 2
- 101000726901 Homo sapiens Neuronal acetylcholine receptor subunit beta-2 Proteins 0.000 description 2
- 101001124900 Homo sapiens PR domain zinc finger protein 8 Proteins 0.000 description 2
- 101000994632 Homo sapiens Potassium voltage-gated channel subfamily A member 2 Proteins 0.000 description 2
- 101000997292 Homo sapiens Potassium voltage-gated channel subfamily B member 1 Proteins 0.000 description 2
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 2
- 101000742002 Homo sapiens Prickle-like protein 1 Proteins 0.000 description 2
- 101000577696 Homo sapiens Proline-rich transmembrane protein 2 Proteins 0.000 description 2
- 101000797874 Homo sapiens Putative bifunctional UDP-N-acetylglucosamine transferase and deubiquitinase ALG13 Proteins 0.000 description 2
- 101000927773 Homo sapiens Rho guanine nucleotide exchange factor 9 Proteins 0.000 description 2
- 101000709238 Homo sapiens Serine/threonine-protein kinase SIK1 Proteins 0.000 description 2
- 101000585079 Homo sapiens Syntaxin-1B Proteins 0.000 description 2
- 101001071076 Homo sapiens Translation factor GUF1, mitochondrial Proteins 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108010050332 IQ motif containing GTPase activating protein 1 Proteins 0.000 description 2
- 102100025458 Inosine triphosphate pyrophosphatase Human genes 0.000 description 2
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 description 2
- 108010038888 KCNQ3 Potassium Channel Proteins 0.000 description 2
- 102100026895 KICSTOR complex protein SZT2 Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 102100030928 Lactosylceramide alpha-2,3-sialyltransferase Human genes 0.000 description 2
- 102100038889 Laforin, isoform 9 Human genes 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102100020983 Lysosome membrane protein 2 Human genes 0.000 description 2
- 244000024873 Mentha crispa Species 0.000 description 2
- 235000014749 Mentha crispa Nutrition 0.000 description 2
- 235000016257 Mentha pulegium Nutrition 0.000 description 2
- 244000246386 Mentha pulegium Species 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- 102100040273 Mitochondrial glutamate carrier 1 Human genes 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 102100035585 Neuronal acetylcholine receptor subunit alpha-2 Human genes 0.000 description 2
- 102100039909 Neuronal acetylcholine receptor subunit alpha-4 Human genes 0.000 description 2
- 102100030912 Neuronal acetylcholine receptor subunit beta-2 Human genes 0.000 description 2
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 2
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 201000009916 Postpartum depression Diseases 0.000 description 2
- 102100034369 Potassium voltage-gated channel subfamily A member 2 Human genes 0.000 description 2
- 102100034310 Potassium voltage-gated channel subfamily B member 1 Human genes 0.000 description 2
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 2
- 102100034354 Potassium voltage-gated channel subfamily KQT member 2 Human genes 0.000 description 2
- 102100034360 Potassium voltage-gated channel subfamily KQT member 3 Human genes 0.000 description 2
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 2
- 102100038630 Prickle-like protein 1 Human genes 0.000 description 2
- 102100028840 Proline-rich transmembrane protein 2 Human genes 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- 102100032337 Putative bifunctional UDP-N-acetylglucosamine transferase and deubiquitinase ALG13 Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000031977 Rare epilepsy Diseases 0.000 description 2
- 102100034419 Ras GTPase-activating-like protein IQGAP1 Human genes 0.000 description 2
- 101150039863 Rich gene Proteins 0.000 description 2
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 2
- 108091005488 SCARB2 Proteins 0.000 description 2
- 108091006426 SLC25A22 Proteins 0.000 description 2
- 108091006296 SLC2A1 Proteins 0.000 description 2
- 102000005028 SLC6A1 Human genes 0.000 description 2
- 108060007759 SLC6A1 Proteins 0.000 description 2
- 206010039740 Screaming Diseases 0.000 description 2
- 101710083834 Serine/threonine-protein kinase SIK1 Proteins 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 102100033927 Sodium- and chloride-dependent GABA transporter 1 Human genes 0.000 description 2
- 102100034250 Solute carrier family 12 member 5 Human genes 0.000 description 2
- 102100035210 Solute carrier family 13 member 5 Human genes 0.000 description 2
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102100029931 Syntaxin-1B Human genes 0.000 description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 102100039197 Ubiquitin-like modifier-activating enzyme 5 Human genes 0.000 description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 description 2
- 244000263375 Vanilla tahitensis Species 0.000 description 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 2
- 108010036639 WW Domain-Containing Oxidoreductase Proteins 0.000 description 2
- 102000012163 WW Domain-Containing Oxidoreductase Human genes 0.000 description 2
- 108700029631 X-Linked Genes Proteins 0.000 description 2
- ISLUIHYFJMYECW-BSMCXZHXSA-N [(3s,5r,6r,8s,9s,10r,13r,14s,17r)-5,6-dibromo-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-1,2,3,4,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@]1(Br)[C@H](Br)C2)[C@@H](OC(C)=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 ISLUIHYFJMYECW-BSMCXZHXSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 208000028311 absence seizure Diseases 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- SPTSIOTYTJZTOG-UHFFFAOYSA-N acetic acid;octadecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O SPTSIOTYTJZTOG-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 description 2
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000002457 bidirectional effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 230000007177 brain activity Effects 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229920003086 cellulose ether Polymers 0.000 description 2
- 229920003174 cellulose-based polymer Polymers 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 229960001403 clobazam Drugs 0.000 description 2
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 description 2
- 229960004362 clorazepate Drugs 0.000 description 2
- XDDJGVMJFWAHJX-UHFFFAOYSA-N clorazepic acid Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)O)N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 229960005168 croscarmellose Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- HBGGXOJOCNVPFY-UHFFFAOYSA-N diisononyl phthalate Chemical group CC(C)CCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCC(C)C HBGGXOJOCNVPFY-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940018602 docusate Drugs 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 208000028329 epileptic seizure Diseases 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 229960002200 flunitrazepam Drugs 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 230000005861 gene abnormality Effects 0.000 description 2
- 238000012224 gene deletion Methods 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 235000015201 grapefruit juice Nutrition 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 235000001050 hortel pimenta Nutrition 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 2
- 229960004002 levetiracetam Drugs 0.000 description 2
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 2
- 229960001518 levocarnitine Drugs 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 229960004391 lorazepam Drugs 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229940102398 methyl anthranilate Drugs 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 229960004798 minaxolone Drugs 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000004220 muscle function Effects 0.000 description 2
- 230000008587 neuronal excitability Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 230000008452 non REM sleep Effects 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 239000001301 oxygen Chemical class 0.000 description 2
- 230000001314 paroxysmal effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229940050929 polyethylene glycol 3350 Drugs 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229950009829 prasterone sulfate Drugs 0.000 description 2
- 229960001233 pregabalin Drugs 0.000 description 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 150000003146 progesterones Chemical class 0.000 description 2
- 239000000092 prognostic biomarker Substances 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000008132 psychomotor development Effects 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229960003014 rufinamide Drugs 0.000 description 2
- POGQSBRIGCQNEG-UHFFFAOYSA-N rufinamide Chemical compound N1=NC(C(=O)N)=CN1CC1=C(F)C=CC=C1F POGQSBRIGCQNEG-UHFFFAOYSA-N 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- ZMQAAUBTXCXRIC-UHFFFAOYSA-N safrole Chemical compound C=CCC1=CC=C2OCOC2=C1 ZMQAAUBTXCXRIC-UHFFFAOYSA-N 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 206010039722 scoliosis Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 229960003885 sodium benzoate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000003195 sodium channel blocking agent Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229960001790 sodium citrate Drugs 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 210000001103 thalamus Anatomy 0.000 description 2
- 229960004394 topiramate Drugs 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 229960004418 trolamine Drugs 0.000 description 2
- 229960005318 vigabatrin Drugs 0.000 description 2
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- 229910001233 yttria-stabilized zirconia Inorganic materials 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- XOYCLJDJUKHHHS-LHBOOPKSSA-N (2s,3s,4s,5r,6r)-6-[[(2s,3s,5r)-3-amino-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@H](O2)C(O)=O)O)[C@@H](N)C1 XOYCLJDJUKHHHS-LHBOOPKSSA-N 0.000 description 1
- DUHUCHOQIDJXAT-CSXWOMMHSA-N (3r,5r,8s,9s,10s,13s,14s,17s)-17-acetyl-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-11-one Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-CSXWOMMHSA-N 0.000 description 1
- NUFKRGBSZPCGQB-FLBSXDLDSA-N (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid;pentahydrate Chemical compound O.O.O.O.O.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C NUFKRGBSZPCGQB-FLBSXDLDSA-N 0.000 description 1
- FJIKWRGCXUCUIG-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C([C@H](O)N=1)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1Cl FJIKWRGCXUCUIG-HNNXBMFYSA-N 0.000 description 1
- ALARQZQTBTVLJV-CYBMUJFWSA-N (5r)-5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione Chemical compound C=1C=CC=CC=1[C@]1(CC)C(=O)NC(=O)N(C)C1=O ALARQZQTBTVLJV-CYBMUJFWSA-N 0.000 description 1
- VZRAKVPDZIQRGT-WZBAXQLOSA-N (8r,9s,10s,13r,14s,17r)-17-ethenyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C=C)[C@@H]4[C@@H]3CCC21 VZRAKVPDZIQRGT-WZBAXQLOSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 102100030390 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 Human genes 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- KHXKBAHELKTPNG-UHFFFAOYSA-N 2-(2,3-dihydroxyphenyl)ethene-1,1,2-triol Chemical compound OC(O)=C(O)C1=CC=CC(O)=C1O KHXKBAHELKTPNG-UHFFFAOYSA-N 0.000 description 1
- GGCILSXUAHLDMF-CQSZACIVSA-N 2-[[2-[(3r)-3-aminopiperidin-1-yl]-5-bromo-6-oxopyrimidin-1-yl]methyl]benzonitrile Chemical compound C1[C@H](N)CCCN1C1=NC=C(Br)C(=O)N1CC1=CC=CC=C1C#N GGCILSXUAHLDMF-CQSZACIVSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- QGXBDMJGAMFCBF-BNSUEQOYSA-N 3alpha-hydroxy-5beta-androstan-17-one Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@@H]21 QGXBDMJGAMFCBF-BNSUEQOYSA-N 0.000 description 1
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 1
- 108010060511 4-Aminobutyrate Transaminase Proteins 0.000 description 1
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 description 1
- 125000005274 4-hydroxybenzoic acid group Chemical group 0.000 description 1
- ISAVYTVYFVQUDY-UHFFFAOYSA-N 4-tert-Octylphenol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 ISAVYTVYFVQUDY-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- CYKYBWRSLLXBOW-GDYGHMJCSA-N 5-alpha-THDOC Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CC[C@H]21 CYKYBWRSLLXBOW-GDYGHMJCSA-N 0.000 description 1
- QZLYKIGBANMMBK-UGCZWRCOSA-N 5α-Androstane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 description 1
- JWMFYGXQPXQEEM-NUNROCCHSA-N 5β-pregnane Chemical compound C([C@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](CC)[C@@]2(C)CC1 JWMFYGXQPXQEEM-NUNROCCHSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- XBWAZCLHZCFCGK-UHFFFAOYSA-N 7-chloro-1-methyl-5-phenyl-3,4-dihydro-2h-1,4-benzodiazepin-1-ium;chloride Chemical compound [Cl-].C12=CC(Cl)=CC=C2[NH+](C)CCN=C1C1=CC=CC=C1 XBWAZCLHZCFCGK-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 101150012579 ADSL gene Proteins 0.000 description 1
- 102100021176 ATP-sensitive inward rectifier potassium channel 10 Human genes 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102100023056 Adaptin ear-binding coat-associated protein 1 Human genes 0.000 description 1
- 102100020775 Adenylosuccinate lyase Human genes 0.000 description 1
- 108700040193 Adenylosuccinate lyases Proteins 0.000 description 1
- 101710096099 Adhesion G-protein coupled receptor V1 Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010052813 Aerophagia Diseases 0.000 description 1
- 208000037071 Aerophagy Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010058060 Alanine-tRNA ligase Proteins 0.000 description 1
- 108010003133 Aldo-Keto Reductase Family 1 Member C2 Proteins 0.000 description 1
- 102100024089 Aldo-keto reductase family 1 member C2 Human genes 0.000 description 1
- 239000004377 Alitame Substances 0.000 description 1
- 102100036666 Alpha-2B adrenergic receptor Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000208874 Althaea officinalis Species 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 102100022440 Battenin Human genes 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010005177 Blindness cortical Diseases 0.000 description 1
- 206010048409 Brain malformation Diseases 0.000 description 1
- UMSGKTJDUHERQW-UHFFFAOYSA-N Brotizolam Chemical compound C1=2C=C(Br)SC=2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl UMSGKTJDUHERQW-UHFFFAOYSA-N 0.000 description 1
- 208000013576 CDKL5 disease Diseases 0.000 description 1
- 101150016154 CERS1 gene Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 108010045489 Calcium-Activated Potassium Channels Proteins 0.000 description 1
- 102000005702 Calcium-Activated Potassium Channels Human genes 0.000 description 1
- 102100038563 Calcium-binding mitochondrial carrier protein Aralar1 Human genes 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000058074 Carboxypeptidase A6 Human genes 0.000 description 1
- 108700001208 Carboxypeptidase A6 Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100032219 Cathepsin D Human genes 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 102100034505 Ceroid-lipofuscinosis neuronal protein 5 Human genes 0.000 description 1
- 102100034480 Ceroid-lipofuscinosis neuronal protein 6 Human genes 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- CHBRHODLKOZEPZ-UHFFFAOYSA-N Clotiazepam Chemical compound S1C(CC)=CC2=C1N(C)C(=O)CN=C2C1=CC=CC=C1Cl CHBRHODLKOZEPZ-UHFFFAOYSA-N 0.000 description 1
- 235000016795 Cola Nutrition 0.000 description 1
- 235000011824 Cola pachycarpa Nutrition 0.000 description 1
- 208000033001 Complex partial seizures Diseases 0.000 description 1
- 108010087196 Contactin 2 Proteins 0.000 description 1
- 102100040501 Contactin-associated protein 1 Human genes 0.000 description 1
- 102100040499 Contactin-associated protein-like 2 Human genes 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 108010061635 Cystatin B Proteins 0.000 description 1
- 101000923091 Danio rerio Aristaless-related homeobox protein Proteins 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- 102100031675 DnaJ homolog subfamily C member 5 Human genes 0.000 description 1
- 108010036694 Dynamin I Proteins 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 102000016675 EF-hand domains Human genes 0.000 description 1
- 108050006297 EF-hand domains Proteins 0.000 description 1
- 229920005682 EO-PO block copolymer Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101150097883 Epm2a gene Proteins 0.000 description 1
- SIGSNYAYBSJATD-UHFFFAOYSA-N Ethadione Chemical compound CCN1C(=O)OC(C)(C)C1=O SIGSNYAYBSJATD-UHFFFAOYSA-N 0.000 description 1
- CUCHJCMWNFEYOM-UHFFFAOYSA-N Ethyl loflazepate Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)OCC)N=C1C1=CC=CC=C1F CUCHJCMWNFEYOM-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- VMZUTJCNQWMAGF-UHFFFAOYSA-N Etizolam Chemical compound S1C(CC)=CC2=C1N1C(C)=NN=C1CN=C2C1=CC=CC=C1Cl VMZUTJCNQWMAGF-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 102100031562 Excitatory amino acid transporter 2 Human genes 0.000 description 1
- 101150026630 FOXG1 gene Proteins 0.000 description 1
- 208000002091 Febrile Seizures Diseases 0.000 description 1
- 102000014250 Fibroblast growth factor 12 Human genes 0.000 description 1
- 108050003239 Fibroblast growth factor 12 Proteins 0.000 description 1
- OFVXPDXXVSGEPX-UHFFFAOYSA-N Flutoprazepam Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C11)=NCC(=O)N1CC1CC1 OFVXPDXXVSGEPX-UHFFFAOYSA-N 0.000 description 1
- 102100035139 Folate receptor alpha Human genes 0.000 description 1
- 102100020871 Forkhead box protein G1 Human genes 0.000 description 1
- XWLUWCNOOVRFPX-UHFFFAOYSA-N Fosphenytoin Chemical compound O=C1N(COP(O)(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 XWLUWCNOOVRFPX-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000034286 G proteins Human genes 0.000 description 1
- 102000037078 GABA transporters Human genes 0.000 description 1
- 108091006228 GABA transporters Proteins 0.000 description 1
- 101710128580 GATOR complex protein DEPDC5 Proteins 0.000 description 1
- 102400001370 Galanin Human genes 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 102100028501 Galanin peptides Human genes 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 101710178610 Golgi SNAP receptor complex member 2 Proteins 0.000 description 1
- 102100036675 Golgi-associated PDZ and coiled-coil motif-containing protein Human genes 0.000 description 1
- 208000034308 Grand mal convulsion Diseases 0.000 description 1
- 102100040579 Guanidinoacetate N-methyltransferase Human genes 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
- 102100031561 Hamartin Human genes 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 102100031470 Homeobox protein ARX Human genes 0.000 description 1
- 101000583063 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 Proteins 0.000 description 1
- 101000614696 Homo sapiens ATP-sensitive inward rectifier potassium channel 10 Proteins 0.000 description 1
- 101000979313 Homo sapiens Adaptin ear-binding coat-associated protein 1 Proteins 0.000 description 1
- 101000901683 Homo sapiens Battenin Proteins 0.000 description 1
- 101000869010 Homo sapiens Cathepsin D Proteins 0.000 description 1
- 101000710208 Homo sapiens Ceroid-lipofuscinosis neuronal protein 5 Proteins 0.000 description 1
- 101000710215 Homo sapiens Ceroid-lipofuscinosis neuronal protein 6 Proteins 0.000 description 1
- 101000749872 Homo sapiens Contactin-associated protein 1 Proteins 0.000 description 1
- 101000749877 Homo sapiens Contactin-associated protein-like 2 Proteins 0.000 description 1
- 101000912191 Homo sapiens Cystatin-B Proteins 0.000 description 1
- 101000845893 Homo sapiens DnaJ homolog subfamily C member 5 Proteins 0.000 description 1
- 101001028052 Homo sapiens Filamin-binding LIM protein 1 Proteins 0.000 description 1
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 description 1
- 101000860415 Homo sapiens Galanin peptides Proteins 0.000 description 1
- 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 1
- 101001072499 Homo sapiens Golgi-associated PDZ and coiled-coil motif-containing protein Proteins 0.000 description 1
- 101000893897 Homo sapiens Guanidinoacetate N-methyltransferase Proteins 0.000 description 1
- 101000795643 Homo sapiens Hamartin Proteins 0.000 description 1
- 101000923090 Homo sapiens Homeobox protein ARX Proteins 0.000 description 1
- 101001056794 Homo sapiens Inosine triphosphate pyrophosphatase Proteins 0.000 description 1
- 101001046974 Homo sapiens KAT8 regulatory NSL complex subunit 1 Proteins 0.000 description 1
- 101000876418 Homo sapiens Laforin Proteins 0.000 description 1
- 101000882389 Homo sapiens Laforin, isoform 9 Proteins 0.000 description 1
- 101000620451 Homo sapiens Leucine-rich glioma-inactivated protein 1 Proteins 0.000 description 1
- 101000801619 Homo sapiens Long-chain-fatty-acid-CoA ligase ACSBG1 Proteins 0.000 description 1
- 101000575454 Homo sapiens Major facilitator superfamily domain-containing protein 8 Proteins 0.000 description 1
- 101000615498 Homo sapiens Methyl-CpG-binding domain protein 5 Proteins 0.000 description 1
- 101000822103 Homo sapiens Neuronal acetylcholine receptor subunit alpha-7 Proteins 0.000 description 1
- 101001094809 Homo sapiens Polynucleotide 5'-hydroxyl-kinase Proteins 0.000 description 1
- 101000997283 Homo sapiens Potassium voltage-gated channel subfamily C member 1 Proteins 0.000 description 1
- 101000710213 Homo sapiens Protein CLN8 Proteins 0.000 description 1
- 101001066905 Homo sapiens Pyridoxine-5'-phosphate oxidase Proteins 0.000 description 1
- 101000579226 Homo sapiens Renin receptor Proteins 0.000 description 1
- 101000639970 Homo sapiens Sodium- and chloride-dependent GABA transporter 1 Proteins 0.000 description 1
- 101000753197 Homo sapiens Sodium/potassium-transporting ATPase subunit alpha-2 Proteins 0.000 description 1
- 101000640909 Homo sapiens Solute carrier family 12 member 5 Proteins 0.000 description 1
- 101001093944 Homo sapiens Solute carrier family 13 member 5 Proteins 0.000 description 1
- 101000704203 Homo sapiens Spectrin alpha chain, non-erythrocytic 1 Proteins 0.000 description 1
- 101000629629 Homo sapiens Sushi repeat-containing protein SRPX2 Proteins 0.000 description 1
- 101000821100 Homo sapiens Synapsin-1 Proteins 0.000 description 1
- 101000648077 Homo sapiens Syntaxin-binding protein 1 Proteins 0.000 description 1
- 101000976959 Homo sapiens Transcription factor 4 Proteins 0.000 description 1
- 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 description 1
- 101000795659 Homo sapiens Tuberin Proteins 0.000 description 1
- 101000608584 Homo sapiens Ubiquitin-like modifier-activating enzyme 5 Proteins 0.000 description 1
- 101000772888 Homo sapiens Ubiquitin-protein ligase E3A Proteins 0.000 description 1
- 101000723833 Homo sapiens Zinc finger E-box-binding homeobox 2 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 102100022903 KAT8 regulatory NSL complex subunit 1 Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710192391 Laforin Proteins 0.000 description 1
- 208000030979 Language Development disease Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 102100022275 Leucine-rich glioma-inactivated protein 1 Human genes 0.000 description 1
- 102100033564 Long-chain-fatty-acid-CoA ligase ACSBG1 Human genes 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 101150083522 MECP2 gene Proteins 0.000 description 1
- 102100025613 Major facilitator superfamily domain-containing protein 8 Human genes 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 235000014766 Mentha X piperi var citrata Nutrition 0.000 description 1
- 244000007703 Mentha citrata Species 0.000 description 1
- 235000007421 Mentha citrata Nutrition 0.000 description 1
- 235000008660 Mentha x piperita subsp citrata Nutrition 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AJXPJJZHWIXJCJ-UHFFFAOYSA-N Methsuximide Chemical compound O=C1N(C)C(=O)CC1(C)C1=CC=CC=C1 AJXPJJZHWIXJCJ-UHFFFAOYSA-N 0.000 description 1
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 1
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 1
- 102100021292 Methyl-CpG-binding domain protein 5 Human genes 0.000 description 1
- 102100039124 Methyl-CpG-binding protein 2 Human genes 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 235000002431 Monarda citriodora Nutrition 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 206010028923 Neonatal asphyxia Diseases 0.000 description 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 1
- 102100021511 Neuronal acetylcholine receptor subunit alpha-7 Human genes 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101710117737 PR domain zinc finger protein 8 Proteins 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 108020002591 Palmitoyl protein thioesterase Proteins 0.000 description 1
- 102000005327 Palmitoyl protein thioesterase Human genes 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- VQASKUSHBVDKGU-UHFFFAOYSA-N Paramethadione Chemical compound CCC1(C)OC(=O)N(C)C1=O VQASKUSHBVDKGU-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000037158 Partial Epilepsies Diseases 0.000 description 1
- 206010061334 Partial seizures Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- XPFRXWCVYUEORT-UHFFFAOYSA-N Phenacemide Chemical compound NC(=O)NC(=O)CC1=CC=CC=C1 XPFRXWCVYUEORT-UHFFFAOYSA-N 0.000 description 1
- AJOQSQHYDOFIOX-UHFFFAOYSA-N Pheneturide Chemical compound NC(=O)NC(=O)C(CC)C1=CC=CC=C1 AJOQSQHYDOFIOX-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102100035460 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000035992 Postmortem Changes Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 102100034308 Potassium voltage-gated channel subfamily C member 1 Human genes 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
- 101710100261 Proline-rich transmembrane protein 2 Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010065942 Prostaglandin-F synthase Proteins 0.000 description 1
- 102100034479 Protein CLN8 Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 235000010401 Prunus avium Nutrition 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 235000014441 Prunus serotina Nutrition 0.000 description 1
- 240000008296 Prunus serotina Species 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 102100034407 Pyridoxine-5'-phosphate oxidase Human genes 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- IKMPWMZBZSAONZ-UHFFFAOYSA-N Quazepam Chemical compound FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12 IKMPWMZBZSAONZ-UHFFFAOYSA-N 0.000 description 1
- 101150058540 RAC1 gene Proteins 0.000 description 1
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 1
- 102100028254 Renin receptor Human genes 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 101710128376 Rho guanine nucleotide exchange factor 9 Proteins 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 229940126644 SAGE-718 Drugs 0.000 description 1
- 102100030680 SH3 and multiple ankyrin repeat domains protein 2 Human genes 0.000 description 1
- 102100030681 SH3 and multiple ankyrin repeat domains protein 3 Human genes 0.000 description 1
- 101710101741 SH3 and multiple ankyrin repeat domains protein 3 Proteins 0.000 description 1
- 101710067890 SHANK2 Proteins 0.000 description 1
- 108091006634 SLC12A5 Proteins 0.000 description 1
- 108091006587 SLC13A5 Proteins 0.000 description 1
- 102000012980 SLC1A2 Human genes 0.000 description 1
- 108091006419 SLC25A12 Proteins 0.000 description 1
- 208000020764 Sensation disease Diseases 0.000 description 1
- 208000007888 Sinus Tachycardia Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 101710104414 Sodium- and chloride-dependent GABA transporter 1 Proteins 0.000 description 1
- 102100021955 Sodium/potassium-transporting ATPase subunit alpha-2 Human genes 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010019965 Spectrin Proteins 0.000 description 1
- 102000005890 Spectrin Human genes 0.000 description 1
- 102100031874 Spectrin alpha chain, non-erythrocytic 1 Human genes 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 206010042008 Stereotypy Diseases 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- HMHVCUVYZFYAJI-UHFFFAOYSA-N Sultiame Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1S(=O)(=O)CCCC1 HMHVCUVYZFYAJI-UHFFFAOYSA-N 0.000 description 1
- 102100026826 Sushi repeat-containing protein SRPX2 Human genes 0.000 description 1
- 102100021905 Synapsin-1 Human genes 0.000 description 1
- 102100025293 Syntaxin-binding protein 1 Human genes 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 229920002359 Tetronic® Polymers 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100037116 Transcription elongation factor 1 homolog Human genes 0.000 description 1
- 102100023489 Transcription factor 4 Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108010039203 Tripeptidyl-Peptidase 1 Proteins 0.000 description 1
- 102100034197 Tripeptidyl-peptidase 1 Human genes 0.000 description 1
- 102100031638 Tuberin Human genes 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 101710191389 Ubiquitin-like modifier-activating enzyme 5 Proteins 0.000 description 1
- 102100030434 Ubiquitin-protein ligase E3A Human genes 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 102100025330 Voltage-dependent P/Q-type calcium channel subunit alpha-1A Human genes 0.000 description 1
- 102100025482 Voltage-dependent T-type calcium channel subunit alpha-1H Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000027642 X-Linked Genetic disease Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 102100028458 Zinc finger E-box-binding homeobox 2 Human genes 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 229950006487 acebrochol Drugs 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- QRJOQYLXZPQQMX-FWROMSNXSA-N acetic acid [2-[(3R,5S,8S,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-11-oxo-1,2,3,4,5,6,7,8,9,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] ester Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)COC(=O)C)[C@@]2(C)CC1=O QRJOQYLXZPQQMX-FWROMSNXSA-N 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229950000888 alfadolone acetate Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 235000019409 alitame Nutrition 0.000 description 1
- 108010009985 alitame Proteins 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940125516 allosteric modulator Drugs 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000007529 anxiety like behavior Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical class [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000005849 atypical Rett syndrome Diseases 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000004009 axon guidance Effects 0.000 description 1
- MJCBWPMBFCUHBP-NPULLEENSA-N barbexaclone Chemical compound CN[C@@H](C)CC1CCCCC1.C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O MJCBWPMBFCUHBP-NPULLEENSA-N 0.000 description 1
- 229960002910 barbexaclone Drugs 0.000 description 1
- 235000011956 bavarian cream Nutrition 0.000 description 1
- 229960005200 beclamide Drugs 0.000 description 1
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 229950010832 bretazenil Drugs 0.000 description 1
- LWUDDYHYYNNIQI-ZDUSSCGKSA-N bretazenil Chemical compound O=C1C2=C(Br)C=CC=C2N2C=NC(C(=O)OC(C)(C)C)=C2[C@@H]2CCCN21 LWUDDYHYYNNIQI-ZDUSSCGKSA-N 0.000 description 1
- 229960002161 brivaracetam Drugs 0.000 description 1
- MSYKRHVOOPPJKU-BDAKNGLRSA-N brivaracetam Chemical compound CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 MSYKRHVOOPPJKU-BDAKNGLRSA-N 0.000 description 1
- 229960003051 brotizolam Drugs 0.000 description 1
- 206010006514 bruxism Diseases 0.000 description 1
- 235000010634 bubble gum Nutrition 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 101150095524 cdd gene Proteins 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 208000025222 central nervous system infectious disease Diseases 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 208000012056 cerebral malformation Diseases 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 230000008131 children development Effects 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 231100001256 chronic oral toxicity Toxicity 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229960002753 cinolazepam Drugs 0.000 description 1
- XAXMYHMKTCNRRZ-UHFFFAOYSA-N cinolazepam Chemical compound C12=CC(Cl)=CC=C2N(CCC#N)C(=O)C(O)N=C1C1=CC=CC=C1F XAXMYHMKTCNRRZ-UHFFFAOYSA-N 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229960003622 clotiazepam Drugs 0.000 description 1
- 229960003932 cloxazolam Drugs 0.000 description 1
- ZIXNZOBDFKSQTC-UHFFFAOYSA-N cloxazolam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN2CCOC21C1=CC=CC=C1Cl ZIXNZOBDFKSQTC-UHFFFAOYSA-N 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 231100000870 cognitive problem Toxicity 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 208000009153 cortical blindness Diseases 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- CHIFCDOIPRCHCF-UHFFFAOYSA-N delorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl CHIFCDOIPRCHCF-UHFFFAOYSA-N 0.000 description 1
- 229950007393 delorazepam Drugs 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229940028937 divalproex sodium Drugs 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 208000019479 dysautonomia Diseases 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003233 eslicarbazepine acetate Drugs 0.000 description 1
- QIALRBLEEWJACW-INIZCTEOSA-N eslicarbazepine acetate Chemical compound CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12 QIALRBLEEWJACW-INIZCTEOSA-N 0.000 description 1
- 229960002336 estazolam Drugs 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- 229960000262 ethadione Drugs 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 229960003533 ethotoin Drugs 0.000 description 1
- SZQIFWWUIBRPBZ-UHFFFAOYSA-N ethotoin Chemical compound O=C1N(CC)C(=O)NC1C1=CC=CC=C1 SZQIFWWUIBRPBZ-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960004759 ethyl loflazepate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229960004404 etizolam Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000009540 excitatory neurotransmission Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229960003528 flurazepam Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- 229950009299 flutoprazepam Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 229960000693 fosphenytoin Drugs 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 150000002231 fructose derivatives Chemical class 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 229960002158 halazepam Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000053370 human PRRT2 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 150000001469 hydantoins Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 230000000870 hyperventilation Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000009539 inhibitory neurotransmission Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 108010029405 inosine triphosphatase Proteins 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000001153 interneuron Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960004423 ketazolam Drugs 0.000 description 1
- PWAJCNITSBZRBL-UHFFFAOYSA-N ketazolam Chemical compound O1C(C)=CC(=O)N2CC(=O)N(C)C3=CC=C(Cl)C=C3C21C1=CC=CC=C1 PWAJCNITSBZRBL-UHFFFAOYSA-N 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000019223 lemon-lime Nutrition 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 229960003019 loprazolam Drugs 0.000 description 1
- UTEFBSAVJNEPTR-RGEXLXHISA-N loprazolam Chemical compound C1CN(C)CCN1\C=C/1C(=O)N2C3=CC=C([N+]([O-])=O)C=C3C(C=3C(=CC=CC=3)Cl)=NCC2=N\1 UTEFBSAVJNEPTR-RGEXLXHISA-N 0.000 description 1
- 229960004033 lormetazepam Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 235000001035 marshmallow Nutrition 0.000 description 1
- 229960002225 medazepam Drugs 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 229960000906 mephenytoin Drugs 0.000 description 1
- GMHKMTDVRCWUDX-UHFFFAOYSA-N mephenytoin Chemical compound C=1C=CC=CC=1C1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960003729 mesuximide Drugs 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 102000031635 methyl-CpG binding proteins Human genes 0.000 description 1
- 108091009877 methyl-CpG binding proteins Proteins 0.000 description 1
- 229960001703 methylphenobarbital Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 208000010594 motor stereotypies Diseases 0.000 description 1
- 230000001921 mouthing effect Effects 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 230000000956 myotropic effect Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000001525 neurosteroidal effect Effects 0.000 description 1
- 229950001981 nimetazepam Drugs 0.000 description 1
- GWUSZQUVEVMBPI-UHFFFAOYSA-N nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 1
- 229960001454 nitrazepam Drugs 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 229960002640 nordazepam Drugs 0.000 description 1
- AKPLHCDWDRPJGD-UHFFFAOYSA-N nordazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CC=C1 AKPLHCDWDRPJGD-UHFFFAOYSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960003274 paramethadione Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960005198 perampanel Drugs 0.000 description 1
- PRMWGUBFXWROHD-UHFFFAOYSA-N perampanel Chemical compound O=C1C(C=2C(=CC=CC=2)C#N)=CC(C=2N=CC=CC=2)=CN1C1=CC=CC=C1 PRMWGUBFXWROHD-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 229960003396 phenacemide Drugs 0.000 description 1
- 229960003877 pheneturide Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960002034 pinazepam Drugs 0.000 description 1
- MFZOSKPPVCIFMT-UHFFFAOYSA-N pinazepam Chemical compound C12=CC(Cl)=CC=C2N(CC#C)C(=O)CN=C1C1=CC=CC=C1 MFZOSKPPVCIFMT-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 229960004856 prazepam Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 229950003432 premazepam Drugs 0.000 description 1
- CNWSHOJSFGGNLC-UHFFFAOYSA-N premazepam Chemical compound C=1N(C)C(C)=C2C=1NC(=O)CN=C2C1=CC=CC=C1 CNWSHOJSFGGNLC-UHFFFAOYSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 208000018290 primary dysautonomia Diseases 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- 150000003145 progesterone derivatives Chemical class 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- BGRWSFIQQPVEML-UHFFFAOYSA-N pyrazolam Chemical compound C12=CC(Br)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=N1 BGRWSFIQQPVEML-UHFFFAOYSA-N 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 229960001964 quazepam Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229950003206 renanolone Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 235000013533 rum Nutrition 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 108091005484 scavenger receptor class B Proteins 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000037322 slow-wave sleep Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 230000037359 steroid metabolism Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000004964 sulfoalkyl group Chemical group 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229960002573 sultiame Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000009534 synaptic inhibition Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- 229960003188 temazepam Drugs 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229960001918 tiagabine Drugs 0.000 description 1
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 1
- 230000009478 tonic inhibition Effects 0.000 description 1
- 208000028500 tonic seizure Diseases 0.000 description 1
- 208000028325 tonic-clonic seizure Diseases 0.000 description 1
- 231100000155 toxicity by organ Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000001926 trapping method Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 229960004453 trimethadione Drugs 0.000 description 1
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000007384 vagal nerve stimulation Effects 0.000 description 1
- 229960001364 valnoctamide Drugs 0.000 description 1
- QRCJOCOSPZMDJY-UHFFFAOYSA-N valnoctamide Chemical compound CCC(C)C(CC)C(N)=O QRCJOCOSPZMDJY-UHFFFAOYSA-N 0.000 description 1
- 229960001930 valpromide Drugs 0.000 description 1
- OMOMUFTZPTXCHP-UHFFFAOYSA-N valpromide Chemical compound CCCC(C(N)=O)CCC OMOMUFTZPTXCHP-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000037221 weight management Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229960002911 zonisamide Drugs 0.000 description 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584403P | 2017-11-10 | 2017-11-10 | |
| US62/584,403 | 2017-11-10 | ||
| PCT/US2018/060037 WO2019094724A1 (en) | 2017-11-10 | 2018-11-09 | Ganaxolone for use in treating genetic epileptic disoders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20200085837A true KR20200085837A (ko) | 2020-07-15 |
Family
ID=66438123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207016409A Ceased KR20200085837A (ko) | 2017-11-10 | 2018-11-09 | 유전적 간질 질환 치료에 사용하기 위한 가낙솔론의 용도 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20190160078A1 (enExample) |
| EP (1) | EP3706755A4 (enExample) |
| JP (3) | JP7312169B2 (enExample) |
| KR (1) | KR20200085837A (enExample) |
| CN (1) | CN111565724A (enExample) |
| AU (2) | AU2018364659A1 (enExample) |
| CA (1) | CA3079259A1 (enExample) |
| EA (1) | EA202091144A1 (enExample) |
| MY (1) | MY204493A (enExample) |
| SG (2) | SG11202004329TA (enExample) |
| WO (1) | WO2019094724A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012304412A1 (en) | 2011-09-08 | 2014-03-27 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| RS59734B1 (sr) | 2012-01-23 | 2020-02-28 | Sage Therapeutics Inc | Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina |
| EP2887944B1 (en) | 2012-08-21 | 2021-10-06 | Sage Therapeutics, Inc. | Allopregnanolone for treating refractory status epilepticus |
| PT2968369T (pt) | 2013-03-13 | 2018-12-05 | Sage Therapeutics Inc | Esteroides neuroativos e métodos para o seu uso |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| KR102614507B1 (ko) | 2013-04-17 | 2023-12-19 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| PL2986624T3 (pl) | 2013-04-17 | 2020-11-16 | Sage Therapeutics, Inc. | Neuroaktywne steroidy 19-NOR do stosowania w sposobach leczenia |
| CA3199003A1 (en) | 2013-07-19 | 2015-01-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| HUE052308T2 (hu) | 2013-08-23 | 2021-04-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásuk |
| WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CN117024502A (zh) | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| EP3206493B1 (en) | 2014-10-16 | 2020-05-06 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3719029A1 (en) | 2014-11-27 | 2020-10-07 | Sage Therapeutics, Inc. | Compositions for inducing sedation |
| ES2857082T3 (es) | 2015-01-26 | 2021-09-28 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| EP3319610A4 (en) | 2015-07-06 | 2019-03-06 | Sage Therapeutics, Inc. | OXYSTEROLS AND METHOD OF USE THEREOF |
| CN113292623A (zh) | 2015-07-06 | 2021-08-24 | 萨奇治疗股份有限公司 | 孕甾醇及其使用方法 |
| PT3319612T (pt) | 2015-07-06 | 2021-08-24 | Sage Therapeutics Inc | Oxisteróis e métodos de utilização dos mesmos |
| AU2017229656B2 (en) | 2016-03-08 | 2022-09-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2921010T3 (es) | 2016-04-01 | 2022-08-16 | Sage Therapeutics Inc | Oxisteroles y procedimientos de uso de los mismos |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| ES2884071T3 (es) | 2016-07-07 | 2021-12-10 | Sage Therapeutics Inc | 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| KR20230079470A (ko) | 2016-08-23 | 2023-06-07 | 세이지 테라퓨틱스, 인크. | 결정질 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 |
| ES2935057T3 (es) | 2016-09-30 | 2023-03-01 | Sage Therapeutics Inc | C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA |
| BR112019008032A2 (pt) | 2016-10-18 | 2019-09-03 | Sage Therapeutics, Inc. | oxiesteróis e métodos de uso dos mesmos |
| EP4105223B1 (en) | 2016-10-18 | 2025-04-30 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| CA3123248A1 (en) * | 2018-12-14 | 2020-06-18 | Praxis Precision Medicines, Inc. | Methods for the treatment of depression |
| WO2020135454A1 (zh) * | 2018-12-26 | 2020-07-02 | 张家口华健致远生物科技有限公司 | 一类类固醇化合物及其用途 |
| WO2020243488A1 (en) | 2019-05-31 | 2020-12-03 | Sage Therapeutics, Inc. | Neuroactive steroids and compositions thereof |
| CA3146857A1 (en) | 2019-07-11 | 2021-01-14 | Praxis Precision Medicines, Inc. | Formulations of t-type calcium channel modulators and methods of use thereof |
| CN114727989A (zh) * | 2019-10-02 | 2022-07-08 | 普拉西斯精密医药公司 | Gaba-a受体正变构调节剂与nmda拮抗剂、nmda负变构调节剂或nmda部分激动剂的组合 |
| MX2022006014A (es) | 2019-12-06 | 2022-06-22 | Marinus Pharmaceuticals Inc | Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa. |
| IL297642A (en) * | 2020-04-29 | 2022-12-01 | Praxis Prec Medicines Inc | Methods for using t-type calcium channel modulators |
| CN114304068B (zh) * | 2020-09-30 | 2025-07-18 | 中国科学院脑科学与智能技术卓越创新中心 | 癫痫动物模型的制备及其应用 |
| WO2022125408A1 (en) * | 2020-12-07 | 2022-06-16 | Marinus Pharmaceuticals, Inc | Use of ganaxolone in treating an epilepsy disorder |
| US20230321116A1 (en) * | 2022-02-16 | 2023-10-12 | Lipocine Inc. | 3Alpha-OH-5Beta-Pregnan-20-One Compositions and Methods for Treating Central Nervous System Disorders |
| WO2023060067A1 (en) * | 2021-10-04 | 2023-04-13 | Marinus Pharmaceuticals, Inc. | Amorphous solid dispersion ganaxolone formulation |
| EP4412619A4 (en) | 2021-10-04 | 2025-11-12 | Marinus Pharmaceuticals Inc | GANAXOLONE FOR THE TREATMENT OF BOURNEVILLE'S TUBEROUS SCLEROSIS AND EPILEPTIC DISORDERS |
| CN119604281A (zh) * | 2022-06-02 | 2025-03-11 | 来普卡公司 | 治疗癫痫的方法和组合物 |
| WO2024257008A1 (en) * | 2023-06-13 | 2024-12-19 | Biostrike Unipessoal Lda | Compounds for diagnosing and treating epilepsy syndromes, methods and uses thereof |
| WO2025248486A1 (en) * | 2024-05-29 | 2025-12-04 | Biostrike Unipessoal Lda | Compounds for preventing sudden death in epilepsy (sudep), methods and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5556847A (en) * | 1994-10-27 | 1996-09-17 | Duquesne University Of The Holy Ghost | Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors |
| US5888996A (en) * | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| RS59734B1 (sr) * | 2012-01-23 | 2020-02-28 | Sage Therapeutics Inc | Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina |
| EP2887944B1 (en) * | 2012-08-21 | 2021-10-06 | Sage Therapeutics, Inc. | Allopregnanolone for treating refractory status epilepticus |
| US9629853B2 (en) * | 2014-05-21 | 2017-04-25 | Wisconsin Alumni Research Foundation | Uses of ganaxolone |
| EP4059522A1 (en) * | 2015-02-06 | 2022-09-21 | Marinus Pharmaceuticals, Inc. | Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders |
| EA036155B1 (ru) * | 2015-10-16 | 2020-10-06 | Маринус Фармасьютикалс, Инк. | Инъекционные составы нейростероида, содержащие наночастицы |
| AU2017229656B2 (en) | 2016-03-08 | 2022-09-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MX2019001669A (es) * | 2016-08-11 | 2019-09-27 | Ovid Therapeutics Inc | Metodos y composiciones para el tratamiento de trastornos epilepticos. |
| KR20190137839A (ko) * | 2017-04-18 | 2019-12-11 | 마리누스 파마슈티컬스 인코포레이티드 | 지속 방출 주사용 뉴로스테로이드 제제 |
-
2018
- 2018-11-09 US US16/185,677 patent/US20190160078A1/en not_active Abandoned
- 2018-11-09 SG SG11202004329TA patent/SG11202004329TA/en unknown
- 2018-11-09 MY MYPI2020002311A patent/MY204493A/en unknown
- 2018-11-09 SG SG10202110563YA patent/SG10202110563YA/en unknown
- 2018-11-09 KR KR1020207016409A patent/KR20200085837A/ko not_active Ceased
- 2018-11-09 EP EP18876989.7A patent/EP3706755A4/en active Pending
- 2018-11-09 AU AU2018364659A patent/AU2018364659A1/en not_active Abandoned
- 2018-11-09 WO PCT/US2018/060037 patent/WO2019094724A1/en not_active Ceased
- 2018-11-09 EA EA202091144A patent/EA202091144A1/ru unknown
- 2018-11-09 CA CA3079259A patent/CA3079259A1/en active Pending
- 2018-11-09 CN CN201880085880.3A patent/CN111565724A/zh active Pending
- 2018-11-09 JP JP2020526304A patent/JP7312169B2/ja active Active
-
2022
- 2022-03-24 US US17/703,331 patent/US20220249515A1/en not_active Abandoned
-
2023
- 2023-07-07 JP JP2023112339A patent/JP2023153783A/ja active Pending
-
2024
- 2024-03-21 US US18/612,277 patent/US20250082651A1/en active Pending
- 2024-10-15 AU AU2024227357A patent/AU2024227357A1/en not_active Abandoned
-
2025
- 2025-04-16 JP JP2025067224A patent/JP2025118661A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202004329TA (en) | 2020-06-29 |
| US20220249515A1 (en) | 2022-08-11 |
| AU2018364659A1 (en) | 2020-05-28 |
| SG10202110563YA (en) | 2021-11-29 |
| JP2023153783A (ja) | 2023-10-18 |
| CN111565724A (zh) | 2020-08-21 |
| JP7312169B2 (ja) | 2023-07-20 |
| JP2021502403A (ja) | 2021-01-28 |
| EA202091144A1 (ru) | 2020-09-16 |
| MY204493A (en) | 2024-08-30 |
| WO2019094724A8 (en) | 2022-10-06 |
| US20190160078A1 (en) | 2019-05-30 |
| EP3706755A1 (en) | 2020-09-16 |
| US20250082651A1 (en) | 2025-03-13 |
| AU2024227357A1 (en) | 2024-10-31 |
| WO2019094724A1 (en) | 2019-05-16 |
| EP3706755A4 (en) | 2021-11-10 |
| JP2025118661A (ja) | 2025-08-13 |
| CA3079259A1 (en) | 2019-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250082651A1 (en) | Ganaxolone for use in treating genetic epileptic disorders | |
| US20230051859A1 (en) | Methods of increasing tonic inhibition and treating secondary insomnia | |
| CN105744932B (zh) | 用于治疗神经障碍的包含托拉塞米和巴氯芬的组合物 | |
| Yanai et al. | Safety considerations in the management of allergic diseases: focus on antihistamines | |
| US11266662B2 (en) | Ganaxolone for use in prophylaxis and treatment of postpartum depression | |
| JP2022521446A (ja) | 発作制御を改善するための製剤 | |
| US20220008398A1 (en) | Gaboxadol for reducing risk of suicide and rapid relief of depression | |
| CN108289870A (zh) | 治疗特定患者群体的神经变性病症的方法 | |
| JP2021500342A (ja) | 神経変性疾患の治療薬 | |
| US20240374614A1 (en) | Ganaxolone for use in treating tuberous sclerosis complex | |
| TW202425995A (zh) | 減少與神經退化疾病相關的神經退化的方法 | |
| CN110831590A (zh) | 含有培马贝特的医药 | |
| US20250032514A1 (en) | Compositions and methods for the treatment of various diseases | |
| US20230364109A1 (en) | Ganaxolone for use in treatment of super refractory status epilepticus | |
| Malaspina et al. | Disorders of the Motor Cells: The Motor Neuron Diseases | |
| TW202539621A (zh) | 用於治療巴金森氏症的治療劑 | |
| BR112020007657B1 (pt) | Uso de leucina, acetil-leucina ou um sal farmaceuticamente aceitável da mesma para tratamento da síndrome das pernas inquietas (rls) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20200608 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20211101 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230912 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20240829 Comment text: Decision to Refuse Application Patent event code: PE06012S01D |